Business Context and Reporting Period
This Form 8-K is a current report filed by Trxade Group, Inc. (trading symbol: MEDS) on April 14, 2020. The filing details significant corporate governance actions, including the approval of executive and director compensation packages, the granting of equity awards, and the execution of a new employment agreement with the Chief Executive Officer. The company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics and Equity Activity
The filing does not provide standard financial performance metrics such as revenue, net income, cash flow, or debt levels for the reporting period. Instead, it focuses on equity-based compensation and capital structure changes:
- Stock Price: The closing sales price of common stock on the grant date (April 14, 2020) was $6.12 per share.
- Employee Options: 31,750 options granted to employees with an exercise price of $6.12 and a 5-year term.
- Executive Bonuses (2019): 74,484 shares awarded to CEO Suren Ajjarapu and 50,000 shares to President Prashant Patel.
- CEO Performance Shares: 49,020 restricted shares awarded to the CEO, subject to specific 2020 performance metrics.
- Director Compensation: Independent directors received an annual retainer of $35,000 plus restricted stock valued at $55,000 annually. Three directors received 8,987 shares each.
- Other Grants: 12,500 restricted shares to the CFO and 5,000 to legal counsel.
Material Changes and Executive Agreements
The primary material change reported is the execution of a new employment agreement with CEO Suren Ajjarapu, effective April 14, 2020, superseding his prior agreement. Key terms include:
- Term: Extends through December 31, 2025, with automatic one-year renewals unless notice is given.
- Compensation: Base salary of $300,000 annually, plus a performance bonus of up to 100% of base salary.
- Salary Increase Mechanism: If the CEO meets at least 70% of annual performance metrics, his base salary increases by 20% cumulatively.
- 2020 Performance Metrics:
- Revenue goal of $12.5 million (50% vesting).
- 50,000 Bonum Health patients (30% vesting).
- Placement of e-hubs in 100 stores (10% vesting).
- Net operating income of 10% of total sales (20% vesting).
- Severance: In the event of a "Change of Control Termination," the CEO is entitled to a cash severance equal to 3.0 times the sum of his current base salary and last bonus, plus immediate vesting of all equity.
Outlook, Risks, and Contingencies
The filing outlines specific contingencies tied to executive compensation and corporate control:
- Performance Risk: A significant portion of the CEO's equity compensation (49,020 shares) is contingent on meeting the 2020 performance metrics listed above. Failure to meet these targets results in forfeiture of the shares.
- Change of Control Definition: Defined broadly to include acquisition of >50% voting power, mergers, liquidation, or a majority change in the Board of Directors. This triggers accelerated vesting and substantial severance payments.
- Non-Compete: The CEO is restricted from competing with the company for 12 months following termination of employment.
- Equity Dilution: The issuance of approximately 220,000 shares (including options and restricted stock) in this single filing represents a material increase in potential share count, subject to vesting conditions.
Investor Verification Checklist
- Verify the current number of outstanding shares to assess the dilution impact of the 74,484 CEO bonus shares and other grants.
- Confirm the company's progress toward the 2020 revenue goal of $12.5 million and the 50,000 patient target to evaluate the likelihood of CEO equity vesting.
- Review the "Change of Control" provisions in the CEO agreement to understand potential cash outflows in the event of an acquisition.
- Check subsequent filings for the actual issuance of the restricted stock and options described in this report.
- Monitor the company's ability to meet the net operating income target of 10% of total sales, a key metric for executive compensation.